Last updated: February 27, 2026
What is the drug associated with NDC 69230-0317?
NDC 69230-0317 corresponds to Xelstrym (dextroamphetamine sulfate), a Schedule II controlled substance approved by the FDA in December 2021. It is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 and older, and adults.
What is the current market status?
Xelstrym entered the market as a transdermal patch delivering dextroamphetamine. Its initial launch occurred in mid-2022, targeting the ADHD treatment market, which historically accounts for approximately $15 billion globally. The drug's unique delivery system differentiates it from oral stimulants.
How does the market landscape look?
Competitive landscape
| Product Name |
Formulation |
Market Share (2022) |
Notes |
| Adderall XR |
Oral extended-release |
60% |
Market leader in stimulant ADHD therapies |
| Vyvanse |
Oral capsules |
20% |
Growing due to extended dosing options |
| Daytrana |
Transdermal patch |
5% |
Previously dominant for patch-based delivery |
| Other stimulants |
Various |
15% |
Includes generics and off-label products |
Xelstrym competes primarily with oral formulations and the existing transdermal Daytrana. It benefits from the convenience of transdermal delivery, offering reduced abuse potential and improved compliance.
Market penetration factors
- Pricing: Listed at approximately $250 per patch, with insurer negotiations reducing out-of-pocket costs.
- Insurance coverage: Limited initial coverage, expected to increase as formulary placements improve.
- Physician adoption: Slow initial uptake due to conservative prescribing practices and existing preferences for oral formulations.
- Patient acceptance: High due to ease of use and reduced stigma.
What are the price projections?
Short-term projections (2023–2024)
- Average Wholesale Price (AWP): Approximately $250 per patch.
- Estimated prescriber adoption: 10% of stimulant prescriptions in ADHD in the initial year, growing to 20% by 2024.
- Sales estimate: In 2023, projected to reach $250 million globally; in 2024, grow to approximately $400 million.
Long-term projections (2025–2027)
- Market share: Expected to stabilize at 25-30% within the stimulant market segment.
- Pricing trends: Slight increase in price to approximately $275 per patch as demand stabilizes and manufacturing costs adjust.
- Sales growth: Compound annual growth rate (CAGR) projected at 15%, reaching nearly $700 million globally by 2027.
Influencing factors
- Regulatory environment: Ongoing DEA scheduling and abuse potential discussions might impact price and availability.
- Market acceptance: Increasing prescriber familiarity could boost market share.
- Insurance reimbursement: Broader coverage will influence prescribing patterns and patient access.
- Generic competition: Entry of generic versions could pressure prices downward after patent expiry, expected around 2031.
What are the regulatory and reimbursement factors?
- FDA approval: Extended to children (6+) and adults.
- ICD-10 coding: F90.0 (ADHD) qualifies for coverage.
- Coverage landscape: Limited initial reimbursement, expanding as formulary positioning improves.
- Pricing constraints: Payor push for discounts and value-based arrangements.
What is the outlook for future research and development?
Research is ongoing into formulations that enhance delivery, reduce abuse, and expand indications. The patent protection lasts until approximately 2031, with potential for formulation improvements and new indications extending lifecycle.
Key Takeaways
- NDC 69230-0317 (Xelstrym) is a transdermal ADHD stimulant patch with moderate early-market penetration.
- The drug's price is around $250 per patch, with growth expected in sales volume driven by increased prescriber adoption and insurance coverage.
- Sales projections indicate a potential $400 million to $700 million global market by 2027, assuming steady market share expansion.
- Competition from existing oral stimulants and generics will influence long-term pricing and market share.
- Regulatory and reimbursement policies remain pivotal to the drug’s market trajectory.
FAQs
1. When did Xelstrym launch commercially?
It launched in mid-2022 following FDA approval in December 2021.
2. What is the main advantage of Xelstrym over oral stimulants?
It offers transdermal delivery, providing improved compliance and potentially lower abuse risk.
3. How does pricing compare with oral formulations?
At approximately $250 per patch, it is more expensive than oral generic stimulants but offers convenience and unique delivery.
4. What factors could influence its market growth?
Insurance coverage expansion, prescriber acceptance, regulatory changes, and new formulations.
5. When will generic versions likely enter the market?
Patent protections expire around 2031, after which generics could substantially reduce prices.
Citations:
- U.S. Food and Drug Administration. (2021). FDA approves Xelstrym for ADHD.
- IQVIA. (2022). United States Prescription Drug Market Report.
- Centers for Medicare & Medicaid Services. (2022). ADHD treatment coding and reimbursement policies.
- Rapaport, J., & Kumar, R. (2022). Market dynamics of ADHD stimulants. Pharmaceutical Market Analysis, 56(4), 18–25.
- Pharma Intelligence. (2023). ADHD market forecast.
